Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450599 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL1889613 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL1677088 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL20450544 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL20467657 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL24819248 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL20144613 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL20467680 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL1887808 | 1.00 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 | |
| SCHEMBL12666348 | 0.99 | KMT2A (0.44) | KMT2APOLBHDAC8L3MBTL1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127875-A1 | INSULIN DEGLUDEC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NINGBO KUNPENG BIOTECH CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-11358994-B2 | Fatty acid modified human epidermal growth factor | SAINT LOUIS UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358994-B2 | Fatty acid modified human epidermal growth factor | FABP2, EGFR, HGF | KMT2A 3837/4885POLB 1942/4885HDAC8 1865/4885 |
| US-20230127875-A1 | INSULIN DEGLUDEC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | IAPP, INSRR, IDE | KMT2A 4684/4885POLB 3968/4885HDAC8 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.